Loading...

Paul Volberding, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address550 16th. Street
San Francisco CA 94158
Phone415-476-5469
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of MinnesotaM.D.1975
    University of ChicagoA.B.1971
    Collapse Awards and Honors
    Institute of Medicine1999Member

    Collapse Overview 
    Collapse Overview
    I was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. I have worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. I am the PI and co-director with Warner Greene of the NIAID-funded UCSF-Gladstone Center for AIDS Research which supports the large community of HIV investigators in San Francisco. CFAR provides core services, pilot grants to early career stage investigators and supports a comprehensive mentorship program. In the Clinical and Translational Sciences Institute I serve as a member of the Board of Directors and formerly directed the Global Health Program. I stepped down as the Chief of the Medical Service at the San Francisco VA Medical Center in 2012 to become the Director of the UCSF AIDS Research Institute and Director of Research for UCSF Global Health Sciences. The ARI is the comprehensive University organization that links all HIV/AIDS research programs and is the central focus for communications, media relations and philanthropic support for this internationally recognized response to the HIV epidemic. Recently, the ARI became the administrative home for a unique initiative to cure HIV infection funded by amfAR, the Foundation for AIDS Research. I serve as the Director of the amfAR Institute for HIV Cure, working with leading scientists at UCSF, the Gladstone Institute for Virology and Immunology, and Blood Systems Research Institute. My role at GHS as the Director of Research is to convene and sustain the rapidly expanding group of UCSF faculty members conducting research in over 60 countries worldwide, and have helped create a global health Affiliate Faculty Program with over 250 members across the entire University. I also serve as the Associate Chair of the UCSF Department of Medicine for Global Health. My clinical appointment is at the VA where I maintain an active HIV outpatient practice and where I serve on the Board of Directors of the research non-profit, NCIRE. I am the director of the large internet site development and management group, the Center for HIV Information which manages seven sites including the heavily used HIV InSite. I am the Clinical Editor in Chief of the Journal of the Acquired Immunodeficiency Syndromes and serve as the Chair of the Scientific Advisory Board of the Accordia Global AIDS Foundation and the Infectious Diseases Institute at Makerere University in Kampala Uganda. I am a board member of the Pangaea Global AIDS Foundation. I am an active member of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academy of Sciences and am the founder and Board Chair of the International Antiviral Society-USA. On Twitter I am @pvolberding.


    Collapse Research 
    Collapse Research Activities and Funding
    Recent Advances in AIDS and HIV Research
    NIH/NIAID R13AI102630Sep 1, 2012 - Aug 31, 2022
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    SIXTH INTERNATIONAL CONFERENCE ON AIDS
    NIH/NIAID R13AI029901Apr 1, 1990 - Mar 31, 1991
    Role: Principal Investigator
    UCSF-Gladstone Center for AIDS Research
    NIH/NIAID P30AI027763Sep 30, 1988 - Aug 31, 2022
    Role: Principal Investigator
    UCSF-GIVI CENTER FOR AIDS RESEARCH
    NIH/NIMH P30MH059037Sep 30, 1988 - Feb 28, 2003
    Role: Principal Investigator
    LABORATORY AND CLINICAL STUDIES OF AIDS
    NIH/NIAID P01AI024286Feb 1, 1987 - Jun 30, 1992
    Role: Principal Investigator
    SURAMIN IN PATIENTS WITH AIDS AND AIDS RELATED ILLNESSES
    NIH/NIAID N01AI062510Dec 6, 1985
    Role: Principal Investigator
    STUDIES OF ACQUIRED IMMUNE DEFICIENCY SYNDROME
    NIH/NCI U01CA034980May 1, 1983 - Apr 30, 1987
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ. EFFECT OF SHORT-TERM ART INTERRUPTION ON LEVELS OF INTEGRATED HIV DNA. J Virol. 2018 Mar 28. PMID: 29593048.
      View in: PubMed
    2. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding P. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151. PMID: 28208122.
      View in: PubMed
    3. Malekinejad M, Parriott A, Blodgett JC, Horvath H, Shrestha RK, Hutchinson AB, Volberding P, Kahn JG. Effectiveness of community-based condom distribution interventions to prevent HIV in the United States: A systematic review and meta-analysis. PLoS One. 2017; 12(8):e0180718. PMID: 28771484.
      View in: PubMed
    4. Volberding P. How to Survive a Plague: The Next Great HIV/AIDS History. JAMA. 2017 04 04; 317(13):1298-1299. PMID: 28384806.
      View in: PubMed
    5. Volberding P. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Top Antivir Med. 2017 Feb/Mar; 25(1):17-24. PMID: 28402930.
      View in: PubMed
    6. Volberding P, Blattner WA. JAIDS: Transitions, Evolution, and Impact. J Acquir Immune Defic Syndr. 2017 01 01; 74(1):1-2. PMID: 27926666.
      View in: PubMed
    7. Satre DD, Altschuler A, Parthasarathy S, Silverberg MJ, Volberding P, Campbell CI. Implementation and Operational Research: Affordable Care Act Implementation in a California Health Care System Leads to Growth in HIV-Positive Patient Enrollment and Changes in Patient Characteristics. J Acquir Immune Defic Syndr. 2016 Dec 15; 73(5):e76-e82. PMID: 27749602.
      View in: PubMed
    8. Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, Volberding P, Tucker JD. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016 09 20; 16:994. PMID: 27645935; PMCID: PMC5029046.
    9. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 01; 19(1):99-108. PMID: 27576871.
      View in: PubMed
    10. Meffert SM, Shome S, Neylan TC, Musalo K, Fineberg HV, Cooke MM, Volberding P, Goosby EP. Health impact of human rights testimony: harming the most vulnerable? BMJ Glob Health. 2016; 1(1):e000001. PMID: 28588904.
      View in: PubMed
    11. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding P. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. PMID: 27404187; PMCID: PMC5012643.
    12. Chu CE, Wu F, He X, Zhou K, Cheng Y, Cai W, Geng E, Volberding P, Tucker JD. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open Forum Infect Dis. 2016 Apr; 3(2):ofw065. PMID: 27419150; PMCID: PMC4943171.
    13. Tang W, Han L, Best J, Zhang Y, Mollan K, Kim J, Liu F, Hudgens M, Bayus B, Terris-Prestholt F, Galler S, Yang L, Peeling R, Volberding P, Ma B, Xu H, Yang B, Huang S, Fenton K, Wei C, Tucker JD. Crowdsourcing HIV Test Promotion Videos: A Noninferiority Randomized Controlled Trial in China. Clin Infect Dis. 2016 06 01; 62(11):1436-1442. PMID: 27129465; PMCID: PMC4872295 [Available on 06/01/17].
    14. Shearer DW, Volberding P, Schemitsch EH, Cook GE, Slobogean GP, Morshed S. Building Networks for Global Clinical Research: The Basics. J Orthop Trauma. 2015 Dec; 29 Suppl 12:S15-8. PMID: 26584260.
      View in: PubMed
    15. Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, Volberding P, Tucker JD. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res Hum Retroviruses. 2015 Jan; 31(1):78-84. PMID: 25427547; PMCID: PMC4287130.
    16. Lambdin BH, Cheng B, Peter T, Mbwambo J, Apollo T, Dunbar M, Udoh IC, Cattamanchi A, Geng EH, Volberding P. Implementing Implementation Science: An Approach for HIV Prevention, Care and Treatment Programs. Curr HIV Res. 2015; 13(3):244-9. PMID: 25986374; PMCID: PMC4460284.
    17. Volberding P. Highlights of the 2014 International AIDS Conference: update from down under. Top Antivir Med. 2014 Dec-2015 Jan; 22(5):694-7. PMID: 25612178.
      View in: PubMed
    18. Tucker JD, Volberding P, Margolis DM, Rennie S, Barré-Sinoussi F. Words matter: Discussing research towards an HIV cure in research and clinical contexts. J Acquir Immune Defic Syndr. 2014 Nov 01; 67(3):e110-1. PMID: 25314254; PMCID: PMC4199082.
    19. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding P. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):410-25. PMID: 25038359.
      View in: PubMed
    20. Volberding P. HIV cure: the target is clearer but not yet close. Ann Intern Med. 2014 Apr 01; 160(7):505-6. PMID: 24424733.
      View in: PubMed
    21. Volberding P. Solving the mystery of JAIDS. J Acquir Immune Defic Syndr. 2013 Aug 01; 63(4):417. PMID: 23722609.
      View in: PubMed
    22. Das M, Volberding P. Bringing the end in sight: consensus regarding HIV screening strategies. Ann Intern Med. 2013 Jul 02; 159(1):63-4. PMID: 23698261.
      View in: PubMed
    23. El-Sadr WM, Morrison JS, Quinn T, Volberding P. A chronicle of hope and promise: the world as it was, as it is, and as it can be. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S49-50. PMID: 22797739.
      View in: PubMed
    24. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding P. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25; 308(4):387-402. PMID: 22820792.
      View in: PubMed
    25. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 01; 60 Suppl 1:S1-18. PMID: 22688010; PMCID: PMC3413877.
    26. Brown B, Henry K, Volberding P. A clinical view: a trio of HIV specialists offer their take on HIV--then, now, and in the future. Interview by Heidi M Nass. Posit Aware. 2012; 24(4):2-5. PMID: 23094300.
      View in: PubMed
    27. Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):1-8. PMID: 21637110; PMCID: PMC3159837.
    28. Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding P, Baron RB. Clinician attitudes about commercial support of continuing medical education: results of a detailed survey. Arch Intern Med. 2011 May 09; 171(9):840-6. PMID: 21555662.
      View in: PubMed
    29. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. Ann Intern Med. 2010 Oct 05; 153(7):477-9. PMID: 20921548.
      View in: PubMed
    30. Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding P, Demeter LM. Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):132-4. PMID: 20733405; PMCID: PMC2928582.
    31. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding P, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21; 304(3):321-33. PMID: 20639566.
      View in: PubMed
    32. Volberding P, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 03; 376(9734):49-62. PMID: 20609987.
      View in: PubMed
    33. Choi AI, Li Y, Parikh C, Volberding P, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010 Sep; 78(5):478-85. PMID: 20520594; PMCID: PMC3913062.
    34. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding P, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 09; 121(5):651-8. PMID: 20100969; PMCID: PMC2829672.
    35. Linzer M, Warde C, Alexander RW, Demarco DM, Haupt A, Hicks L, Kutner J, Mangione CM, Mechaber H, Rentz M, Riley J, Schuster B, Solomon GD, Volberding P, Ibrahim T. Part-time careers in academic internal medicine: a report from the association of specialty professors part-time careers task force on behalf of the alliance for academic internal medicine. Acad Med. 2009 Oct; 84(10):1395-400. PMID: 19881429.
      View in: PubMed
    36. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009 Sep 24; 23(15):1987-95. PMID: 19696651; PMCID: PMC2888600.
    37. Volberding P. Cohorts, trials, and evidence: expanding our confidence in guidelines for antiretroviral resistance testing. Ann Intern Med. 2009 Jul 21; 151(2):135-6. PMID: 19620166.
      View in: PubMed
    38. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding P. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008 Aug 06; 300(5):555-70. PMID: 18677028.
      View in: PubMed
    39. Choi AI, Rodriguez RA, Bacchetti P, Volberding P, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007 Dec 15; 45(12):1633-9. PMID: 18190326.
      View in: PubMed
    40. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding P, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007 Nov; 18(11):2968-74. PMID: 17942954.
      View in: PubMed
    41. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding P, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007 Dec; 72(11):1380-7. PMID: 17805235.
      View in: PubMed
    42. Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding P. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007 May 15; 44(10):1375-83. PMID: 17443478; PMCID: PMC4075655.
    43. Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):20-9. PMID: 17091020.
      View in: PubMed
    44. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding P. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006 Aug 16; 296(7):827-43. PMID: 16905788.
      View in: PubMed
    45. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding P. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006 Aug-Sep; 14(3):827-43. PMID: 17016878.
      View in: PubMed
    46. Volberding P. The New York case: lessons being learned. Ann Intern Med. 2005 May 17; 142(10):866-8. PMID: 15845950.
      View in: PubMed
    47. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses. 2005 Mar; 21(3):200-6. PMID: 15795525.
      View in: PubMed
    48. Michaels MG, Kaufman C, Volberding P, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation. 2004 Dec 15; 78(11):1582-9. PMID: 15591945.
      View in: PubMed
    49. Henry DH, Volberding P, Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. J Acquir Immune Defic Syndr. 2004 Oct 01; 37(2):1221-7. PMID: 15385728.
      View in: PubMed
    50. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29; 351(5):451-9. PMID: 15282352; PMCID: PMC4113392.
    51. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding P. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14; 292(2):251-65. PMID: 15249575.
      View in: PubMed
    52. Volberding P, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004 May 15; 38(10):1454-63. PMID: 15156485.
      View in: PubMed
    53. Volberding P. Initiating HIV therapy. Timing is critical, controversial. Postgrad Med. 2004 Feb; 115(2):15-8, 21, 24-6. PMID: 15000057.
      View in: PubMed
    54. Volberding P. Opportunities and options for treatment research in resource-constrained settings. Clin Infect Dis. 2003 Jul 01; 37(Suppl 1):S1-3. PMID: 12822126.
      View in: PubMed
    55. Volberding P. HIV therapy in 2003: consensus and controversy. AIDS. 2003 Apr; 17 Suppl 1:S4-11. PMID: 12870525.
      View in: PubMed
    56. Volberding P, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filiced G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D. The pavia consensus statement. AIDS. 2003 Apr; 17 Suppl 1:S170-9. PMID: 12870544.
      View in: PubMed
    57. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003 Mar 28; 17(5):691-8. PMID: 12646792.
      View in: PubMed
    58. Volberding P, Baker KR, Levine AM. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program. 2003; 294-313. PMID: 14633787.
      View in: PubMed
    59. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis. 2002 Dec; 15(6):609-14. PMID: 12821838.
      View in: PubMed
    60. Volberding P. Adherence, resistance, and timing: current issues in the use of new therapies. AIDS Read. 2002 Aug; 12(8):349-50, 356-7, 368. PMID: 12229892.
      View in: PubMed
    61. Rossi SJ, Volberding P, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA. 2002 Jul 10; 288(2):241-3. PMID: 12095390.
      View in: PubMed
    62. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding P. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10; 288(2):222-35. PMID: 12095387.
      View in: PubMed
    63. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002 Jul 01; 18(10):685-93. PMID: 12167274.
      View in: PubMed
    64. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis. 2002 May 15; 185 Suppl 2:S110-4. PMID: 12001031.
      View in: PubMed
    65. Volberding P, Sullivan P. Introduction: the importance of identifying and treating complications of human immunodeficiency virus disease. J Infect Dis. 2002 May 15; 185 Suppl 2:S103-4. PMID: 12001029.
      View in: PubMed
    66. Volberding P. Who cares for AIDS? J Gen Intern Med. 2002 Jan; 17(1):82-3. PMID: 11903780; PMCID: PMC1495001.
    67. Gerbert B, Moe JC, Saag MS, Benson CA, Jacobsen DM, Feraios A, Hill ME, Bronstone A, Caspers N, Volberding P. Toward a definition of HIV expertise: a survey of experienced HIV physicians. AIDS Patient Care STDS. 2001 Jun; 15(6):321-30. PMID: 11445014.
      View in: PubMed
    68. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding P. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000 Jan 19; 283(3):381-90. PMID: 10647802.
      View in: PubMed
    69. Volberding P. Advances in the medical management of patients with HIV-1 infection: an overview. AIDS. 1999 Sep; 13 Suppl 1:S1-9. PMID: 10546780.
      View in: PubMed
    70. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding P. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. PMID: 10228057.
      View in: PubMed
    71. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding P. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998 Jul 01; 280(1):78-86. PMID: 9660368.
      View in: PubMed
    72. Volberding P, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 06; 279(17):1343-4. PMID: 9582033.
      View in: PubMed
    73. Volberding P. An aggressive approach to HIV antiretroviral therapy. Hosp Pract (1995). 1998 Jan 15; 33(1):81-4, 87-90, 95-6 passim. PMID: 9464233.
      View in: PubMed
    74. Volberding P. HIV/AIDS. Protease inhibitors vindicated. Lancet. 1997 Dec 20-27; 350 Suppl 3:SIII10. PMID: 9465186.
      View in: PubMed
    75. Ioannidis JP, Bassett R, Hughes MD, Volberding P, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 01; 16(1):22-30. PMID: 9377121.
      View in: PubMed
    76. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding P. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25; 277(24):1962-9. PMID: 9200638.
      View in: PubMed
    77. Deeks SG, Volberding P. HIV-1 protease inhibitors. AIDS Clin Rev. 1997-1998; 145-85. PMID: 9305448.
      View in: PubMed
    78. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Sáag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding P. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10; 276(2):146-54. PMID: 8656507.
      View in: PubMed
    79. Volberding P. Age as a predictor of progression in HIV infection. Lancet. 1996 Jun 08; 347(9015):1569-70. PMID: 8667860.
      View in: PubMed
    80. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding P. HIV viral load markers in clinical practice. Nat Med. 1996 Jun; 2(6):625-9. PMID: 8640545.
      View in: PubMed
    81. Volberding P. Improving the outcomes of care for patients with human immunodeficiency virus infection. N Engl J Med. 1996 Mar 14; 334(11):729-31. PMID: 8594437.
      View in: PubMed
    82. Volberding P. HIV quantification: clinical applications. Lancet. 1996 Jan 13; 347(8994):71-3. PMID: 8538341.
      View in: PubMed
    83. Northfelt DW, Martin FJ, Working P, Volberding P, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996 Jan; 36(1):55-63. PMID: 8932544.
      View in: PubMed
    84. Volberding P, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med. 1995 Aug 17; 333(7):401-7. PMID: 7616988.
      View in: PubMed
    85. Kaplan LD, Shiramizu B, Herndier B, Hahn J, Meeker TC, Ng V, Volberding P, McGrath MS. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Blood. 1995 Apr 01; 85(7):1727-35. PMID: 7535586.
      View in: PubMed
    86. Volberding P, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10; 272(6):437-42. PMID: 7913730.
      View in: PubMed
    87. Volberding P. Treatment dilemmas in HIV infection. Hosp Pract (Off Ed). 1994 Apr 15; 29(4):49-54, 59-60. PMID: 7908297.
      View in: PubMed
    88. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding P, Testa MA. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994 Mar 17; 330(11):738-43. PMID: 7906386.
      View in: PubMed
    89. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding P. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994 Jan; 169(1):28-36. PMID: 7903975.
      View in: PubMed
    90. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding P, Davis LG, Henrard DR, Weller S, Corey L. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15; 119(8):786-93. PMID: 8379600.
      View in: PubMed
    91. Choi S, Lagakos SW, Schooley RT, Volberding P. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 01; 118(9):674-80. PMID: 8096373.
      View in: PubMed
    92. Fischl MA, Krown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, Volberding P, Kahn J, Groopman JE, Feinberg J. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993 Mar; 6(3):259-64. PMID: 8450401.
      View in: PubMed
    93. Koch MA, Volberding P, Lagakos SW, Booth DK, Pettinelli C, Myers MW. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med. 1992 Nov; 152(11):2286-92. PMID: 1359846.
      View in: PubMed
    94. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding P, Crumpacker CS, Beall G. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27; 327(9):581-7. PMID: 1353607.
      View in: PubMed
    95. Kahn JO, Stites DP, Scillian J, Murcar N, Stryker R, Volberding P, Naylor PH, Goldstein AL, Sarin PS, Simmon VF. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS Res Hum Retroviruses. 1992 Aug; 8(8):1321-5. PMID: 1466950.
      View in: PubMed
    96. Hodges TL, Kahn JO, Kaplan LD, Groopman JE, Volberding P, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother. 1991 Dec; 35(12):2580-6. PMID: 1810192; PMCID: PMC245434.
    97. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding P. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991 Jun; 9(6):929-40. PMID: 2033429.
      View in: PubMed
    98. Krogstad DJ, Eveland MR, Lim LL, Volberding P, Sadler BM. Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019. Antimicrob Agents Chemother. 1991 Jun; 35(6):1160-4. PMID: 1929258; PMCID: PMC284304.
    99. Northfelt DW, Kahn JO, Volberding P. Treatment of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr; 5(2):297-310. PMID: 2022595.
      View in: PubMed
    100. Evans LM, Itri LM, Campion M, Wyler-Plaut R, Krown SE, Groopman JE, Goldsweig H, Volberding P, West SB, Mitsuyasu RT. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother (1991). 1991 Feb; 10(1):39-50. PMID: 1826454.
      View in: PubMed
    101. Tappero JW, Berger TG, Kaplan LD, Volberding P, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr. 1991; 4(9):839-46. PMID: 1895204.
      View in: PubMed
    102. Volberding P. Recent advances in the medical management of early HIV disease. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S7-12. PMID: 2005480.
      View in: PubMed
    103. Cooke M, Libman H, Smith MD, Cooney TG, Hollander H, Makadon HJ, Volberding P. Controversies in the management of HIV-related illnesses. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S46-55. PMID: 2005478.
      View in: PubMed
    104. Kahn JO, Kaplan LD, Gambertoglio JG, Bredesen D, Arri CJ, Turin L, Kibort T, Williams RL, Lifson JD, Volberding P. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS. 1990 Dec; 4(12):1197-204. PMID: 2088398.
      View in: PubMed
    105. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding P. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990 Sep 20; 323(12):769-75. PMID: 1975426.
      View in: PubMed
    106. Volberding P, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 05; 322(14):941-9. PMID: 1969115.
      View in: PubMed
    107. Volberding P. Rationale for variations in clinical trial design in different HIV disease stages. J Acquir Immune Defic Syndr. 1990; 3 Suppl 2:S40-4. PMID: 2231301.
      View in: PubMed
    108. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding P, Schooley RT. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 03; 262(17):2405-10. PMID: 2677429.
      View in: PubMed
    109. Jacobson MA, Abrams DI, Volberding P, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36. PMID: 2566637.
      View in: PubMed
    110. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding P. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989 Feb 03; 261(5):719-24. PMID: 2536124.
      View in: PubMed
    111. Volberding P, Kaplan LD. Treatment of AIDS and its attendant malignancies. Prog Clin Biol Res. 1989; 288:459-70. PMID: 2654959.
      View in: PubMed
    112. Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding P. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex. Biotechnol Ther. 1989-1990; 1(3):229-36. PMID: 2562651.
      View in: PubMed
    113. Kahn JO, Kaplan LD, Volberding P, Ziegler JL, Crowe S, Saks SR, Abrams DI. Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. J Acquir Immune Defic Syndr. 1989; 2(3):217-23. PMID: 2498507.
      View in: PubMed
    114. Wong RJ, Volberding P. Providing clinical pharmacy services in an AIDS--oncology ambulatory-care clinic. Am J Hosp Pharm. 1988 Nov; 45(11):2351-4. PMID: 2852473.
      View in: PubMed
    115. Kaplan LD, Hopewell PC, Jaffe H, Goodman PC, Bottles K, Volberding P. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988; 1(1):23-30. PMID: 3265151.
      View in: PubMed
    116. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill P, Volberding P, Poiesz BJ. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA. 1987 Sep 11; 258(10):1347-51. PMID: 3650339.
      View in: PubMed
    117. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding P, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):185-91. PMID: 3299089.
      View in: PubMed
    118. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding P, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):192-7. PMID: 3299090.
      View in: PubMed
    119. Abrams DI, Volberding P. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1987 Jun; 14(2 Suppl 2):43-7. PMID: 3589704.
      View in: PubMed
    120. Kaplan LD, Wolfe PR, Volberding P, Feorino P, Levy JA, Abrams DI, Kiprov D, Wong R, Kaufman L, Gottlieb MS. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am J Med. 1987 Mar 23; 82(3 Spec No):615-20. PMID: 3548350.
      View in: PubMed
    121. Kaplan LD, Wofsy CB, Volberding P. Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. JAMA. 1987 Mar 13; 257(10):1367-74. PMID: 3546745.
      View in: PubMed
    122. Volberding P, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 01; 59(3 Suppl):620-5. PMID: 3492260.
      View in: PubMed
    123. Chaisson RE, Allain JP, Leuther M, Volberding P. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med. 1986 Dec 18; 315(25):1610-1. PMID: 3466034.
      View in: PubMed
    124. Abrams DI, Kaplan LD, McGrath MS, Volberding P. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. AIDS Res. 1986 Dec; 2 Suppl 1:S131-40. PMID: 3828009.
      View in: PubMed
    125. Abrams DI, Volberding P. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):43-7. PMID: 3532335.
      View in: PubMed
    126. Abrams DI, Dilley JW, Maxey LM, Volberding P. Routine care and psychosocial support of the patient with the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May; 70(3):707-20. PMID: 3959664.
      View in: PubMed
    127. Abrams DI, Kiprov DD, Goedert JJ, Sarngadharan MG, Gallo RC, Volberding P. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med. 1986 Jan; 104(1):47-50. PMID: 3000249.
      View in: PubMed
    128. Volberding P, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol. 1985 Dec; 12(4 Suppl 5):2-6. PMID: 3909416.
      View in: PubMed
    129. Volberding P, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Sep; 103(3):335-8. PMID: 4026082.
      View in: PubMed
    130. Kaplan L, Volberding P. Failure (and danger) of mitozantrone in AIDS-related Kaposi's sarcoma. Lancet. 1985 Aug 17; 2(8451):396. PMID: 2862556.
      View in: PubMed
    131. Volberding P, Wofsy CB, Abrams DI. Interferon and interleukin-2 therapy of Kaposi's sarcoma. Adv Exp Med Biol. 1985; 187:151-7. PMID: 3875980.
      View in: PubMed
    132. Abrams DI, Kiprov DD, Volberding P. Isolated thrombocytopenia in homosexual men--longitudinal follow-up. Adv Exp Med Biol. 1985; 187:117-22. PMID: 3929576.
      View in: PubMed
    133. Abrams DI, Mess T, Volberding P. Lymphadenopathy: end-point prodrome? Update of a 36-month prospective study. Adv Exp Med Biol. 1985; 187:73-84. PMID: 2994422.
      View in: PubMed
    134. Moss AR, McCallum G, Volberding P, Bacchetti P, Dritz S. Mortality associated with mode of presentation in the acquired immune deficiency syndrome. J Natl Cancer Inst. 1984 Dec; 73(6):1281-4. PMID: 6334770.
      View in: PubMed
    135. Ziegler JL, Beckstead JA, Volberding P, Abrams DI, Levine AM, Lukes RJ, Gill PS, Burkes RL, Meyer PR, Metroka CE. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 30; 311(9):565-70. PMID: 6611504.
      View in: PubMed
    136. Abrams DI, Lewis BJ, Volberding P. Lymphadenopathy: endpoint or prodrome? Update of a 24-month prospective study. Ann N Y Acad Sci. 1984; 437:207-15. PMID: 6335951.
      View in: PubMed
    137. Abrams DI, Chinn EK, Lewis BJ, Volberding P, Conant MA, Townsend RM. Hematologic manifestations in homosexual men with Kaposi's sarcoma. Am J Clin Pathol. 1984 Jan; 81(1):13-8. PMID: 6704205.
      View in: PubMed